Fatigue News and Research

RSS

Researchers identify risk factors for SARS-CoV-2 reinfection

A team of scientists from the Capital Medical University and Peking University, China, has recently explored the factors responsible for the reactivation of SARS-CoV-2 infection among individuals who have recently recovered from COVID-19. The findings reveal that individuals with lower lymphocyte count or with two or fewer symptoms during the first COVID-19 episode are at higher risk of recurrent infection.

16 Apr 2021

Recovered COVID-19 patients may need only a single vaccine dose, suggests study

People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new research from the Penn Institute of Immunology. The findings, published today in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response.

16 Apr 2021

Feline model of SARS-CoV-2 infection imitates COVID-19 in humans

Researchers in the United States have validated a feline model of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that closely imitates coronavirus disease 2019 (COVID-19) in humans.

15 Apr 2021

More than half of COVID-19 patients report persistent symptoms 12-months after infection

In a new study, appearing on the pre-print server medRxiv*, researchers at the University of Trieste and Istituto Auxologico Italiano IRCCS in Italy report that more than half of patients with previous mild-to-moderate symptomatic COVID-19 complained of the persistence of at least one symptom 12-months after the onset of the illness.

15 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

New digital platform to aid young Aussies living with incurable movement disorder

More than 20,000 young Aussies (under 50 years of age) living with an incurable movement disorder are set to benefit from the launch of an Australian-first digital support platform today (Thursday, April 8, 2021), ahead of World Parkinson’s Day (Sunday, April 11, 2021).

9 Apr 2021

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Eight months after mild COVID-19, one in ten people still has at least one moderate to severe symptom that is perceived as having a negative impact on their work, social or home life. The most common long-term symptoms are a loss of smell and taste and fatigue.

8 Apr 2021

New test for Lyme disease can reliably distinguish between early- and late-stage patients

For those who live in an area blighted by ticks, the threat of Lyme disease can cast a shadow over the joy of spring and summer.

7 Apr 2021

Study shows stronger link between Down syndrome and acute myeloid leukemia

A new large-scale study led by UC Davis Health and UC San Francisco researchers assessed the risks of leukemia in children with Down syndrome.

7 Apr 2021

Temple, Case Western scientists receive $3 million NIH grant to study pathway behind heart failure

Like a bad water pump that fails to circulate coolant in a car engine, a failing heart struggles to pump blood through the body, causing symptoms of fatigue, shortness of breath, and swelling in the legs and feet.

5 Apr 2021

Signal detection theory can be used to better understand cognitive fatigue

A team of New Jersey researchers has shown that changes in perceptual certainty and response bias, two central metrics of signal detection theory (SDT), correlate with changes in cognitive fatigue.

1 Apr 2021

Researchers identify potential trigger of Crohn's disease

People living with the often-debilitating effects of Crohn's disease may finally gain some relief, thanks to ground-breaking research led by McMaster University.

1 Apr 2021

New Phase 1 clinical trial of investigational vaccine against B.1.351 SARS-CoV-2 variant begins

An investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate's safety and immunogenicity in adult volunteers.

31 Mar 2021

New Columbia University center provides specialized care for Lyme and tick-borne diseases

A new center that will provide specialized care for patients with Lyme disease and other tick-borne diseases will begin seeing patients this summer at Columbia University's Vagelos College of Physicians and Surgeons.

31 Mar 2021

Study compares performance of open-label placebo to blinded placebo in IBS patients

For decades, the power of the placebo effect was thought to lie in patients' belief that they were -- or at least, could be -- receiving a pharmacologically active treatment.

30 Mar 2021

First cell-based gene therapy approved by the FDA for treating multiple myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

29 Mar 2021

Long-term complications are common among COVID-19 recovered individuals

A team of scientists from the United Kingdom has recently conducted a multicenter, prospective cohort study to investigate long-term consequences of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Mar 2021

Survey of surge capacity managers captures pandemic preparedness status of the U.S. health care system

A University of Pittsburgh School of Medicine-led survey of dozens of surge capacity managers at hospitals nationwide captures the U.S. health care system's pandemic preparedness status in the months before the first COVID-19 cases were identified in China.

24 Mar 2021

New review of post-acute COVID-19

The first year of the COVID-19 pandemic has taken the lives of millions of people around the world but has also left hundreds with lingering symptoms or completely new symptoms weeks after recovery.

23 Mar 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021